ObjectiveTo study the isolation and antimicrobial resistance of imipenem/cilastatin (IPM)resistant Acinetobacter baumannii (A. baumannii) in a hospital.MethodsClinical specimens were collected from January 2006 to December 2010, except the blood culture was performed with United States BD BACTEC9120 system, the other specimens were cultured and isolated bacteria with routine method ; strains were identified and performed drug sensitive test with Phoenix 100 automatic analysis system and reagents. The metalloβlactamases were detected with 2mercaptopropanoic acid inhibited assays.ResultsOne hundred and fiftyfour (74.03%) IPMresistant A.baumannii strains were mainly isolated from sputum and throat swabs, strains mainly distributed in the following departments: intensive care unit (98 isolates,63.64%), department of neurology (25,16.23%), burn unit (13,8.44%), respiratory department(8, 5.19%), geriatrics department (4, 2.60%), department of general surgery(3,1.95%), and hematological department(3,1.95%) . IPMresistant A.baumannii had the lowest resistant rate to cefoperazone/sulbactam (42.21%), and the resistant rates to the other antimicrobial agents were all >65%. The rate of metalloβlactamaseproducing strains was 14.94%(23/154).ConclusionThe IPMresistant A.baumannii are chiefly from specimens in respiratory tract infection, and the susceptibility to antimicrobial agents is low. The strengthening of the monitor and optimization use of antimicrobial agents is important for controlling the prevalence of IPMresistant A. baumannii in hospitals.